ESMO/X
Jun 14, 2025, 13:43
Tarlatamab and Lurbinectedin-Atezolizumab Combination Therapy Trials Meet Survival Endpoints: Alfredo Addeo in ESMO Daily Reporter
The European Society for Medical Oncology (ESMO) shared a post on X:
“Two studies investigating efficacy of bispecific T-cell engager tarlatamab and lurbinectedin – atezolizumab combination met their primary endpoints of survival.
Read the opinion by Alfredo Addeo in the ESMO Daily Reporter․“
More posts featuring ESMO Daily Reporter on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 16, 2025, 17:55
Jul 16, 2025, 17:38
Jul 16, 2025, 17:37
Jul 16, 2025, 17:04
Jul 16, 2025, 16:51
Jul 16, 2025, 16:34
Jul 16, 2025, 16:18
Jul 16, 2025, 16:06